229 related articles for article (PubMed ID: 25004789)
21. Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Milan A; Abram S; Veglio F
JAMA; 2013 Jul; 310(2):204-5. PubMed ID: 23839757
[No Abstract] [Full Text] [Related]
22. Aldosterone inhibition in patients with heart failure with preserved ejection fraction--reply.
Edelmann F; Wachter R; Pieske B
JAMA; 2013 Jul; 310(2):205-7. PubMed ID: 23839759
[No Abstract] [Full Text] [Related]
23. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.
Beldhuis IE; Myhre PL; Bristow M; Claggett B; Damman K; Fang JC; Fleg JL; McKinlay S; Lewis EF; O'Meara E; Pitt B; Shah SJ; Vardeny O; Voors AA; Pfeffer MA; Solomon SD; Desai AS
J Am Coll Cardiol; 2021 Mar; 77(9):1211-1221. PubMed ID: 33663739
[TBL] [Abstract][Full Text] [Related]
24. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone.
Cohen JB; Schrauben SJ; Zhao L; Basso MD; Cvijic ME; Li Z; Yarde M; Wang Z; Bhattacharya PT; Chirinos DA; Prenner S; Zamani P; Seiffert DA; Car BD; Gordon DA; Margulies K; Cappola T; Chirinos JA
JACC Heart Fail; 2020 Mar; 8(3):172-184. PubMed ID: 31926856
[TBL] [Abstract][Full Text] [Related]
25. Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT).
Fudim M; Kelly JP; Brophy TJ; DeVore AD; Hammill BG; Peterson ED; Pitt B; Yancy C; Fonarow GC; Hernandez AF
Am J Cardiol; 2020 Jun; 125(11):1655-1660. PubMed ID: 32273054
[TBL] [Abstract][Full Text] [Related]
26. Heart failure: Aldosterone antagonism for HFpEF.
Borlaug BA
Nat Rev Cardiol; 2013 May; 10(5):244-6. PubMed ID: 23546445
[No Abstract] [Full Text] [Related]
27. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
Solomon SD; Claggett B; Lewis EF; Desai A; Anand I; Sweitzer NK; O'Meara E; Shah SJ; McKinlay S; Fleg JL; Sopko G; Pitt B; Pfeffer MA;
Eur Heart J; 2016 Feb; 37(5):455-62. PubMed ID: 26374849
[TBL] [Abstract][Full Text] [Related]
28. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
Kapelios CJ; Murrow JR; Nührenberg TG; Montoro Lopez MN
Heart Fail Rev; 2019 May; 24(3):367-377. PubMed ID: 30618017
[TBL] [Abstract][Full Text] [Related]
29. Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Neil CJ; Singh S; Frenneaux M
JAMA; 2013 Jul; 310(2):204. PubMed ID: 23839756
[No Abstract] [Full Text] [Related]
30. Effects of spironolactone treatment in elderly women with heart failure and preserved left ventricular ejection fraction.
Kurrelmeyer KM; Ashton Y; Xu J; Nagueh SF; Torre-Amione G; Deswal A
J Card Fail; 2014 Aug; 20(8):560-8. PubMed ID: 24905296
[TBL] [Abstract][Full Text] [Related]
31. Spironolactone for heart failure with preserved ejection fraction.
Pitt B; Pfeffer MA; Assmann SF; Boineau R; Anand IS; Claggett B; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Harty B; Heitner JF; Kenwood CT; Lewis EF; O'Meara E; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; Yang S; McKinlay SM;
N Engl J Med; 2014 Apr; 370(15):1383-92. PubMed ID: 24716680
[TBL] [Abstract][Full Text] [Related]
32. Diastolic Blood Pressure and Adverse Outcomes in the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) Trial.
Sandesara PB; O'Neal WT; Kelli HM; Topel M; Samman-Tahhan A; Sperling LS
J Am Heart Assoc; 2018 Feb; 7(5):. PubMed ID: 29475874
[TBL] [Abstract][Full Text] [Related]
33. Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial.
Selvaraj S; Claggett B; Shah SJ; Anand I; Rouleau JL; Desai AS; Lewis EF; Pitt B; Sweitzer NK; Pfeffer MA; Solomon SD
Eur J Heart Fail; 2018 Mar; 20(3):483-490. PubMed ID: 29148144
[TBL] [Abstract][Full Text] [Related]
34. Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.
Vardeny O; Claggett B; Vaduganathan M; Beldhuis I; Rouleau J; O'Meara E; Anand IS; Shah SJ; Sweitzer NK; Fang JC; Desai AS; Lewis EF; Pitt B; Pfeffer MA; Solomon SD;
JACC Heart Fail; 2019 Dec; 7(12):1022-1028. PubMed ID: 31779923
[TBL] [Abstract][Full Text] [Related]
35. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
[TBL] [Abstract][Full Text] [Related]
36. Defining diastolic heart failure and identifying effective therapies.
Cleland JG; Pellicori P
JAMA; 2013 Feb; 309(8):825-6. PubMed ID: 23443447
[No Abstract] [Full Text] [Related]
37. Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease.
Beldhuis IE; Myhre PL; Claggett B; Damman K; Fang JC; Lewis EF; O'Meara E; Pitt B; Shah SJ; Voors AA; Pfeffer MA; Solomon SD; Desai AS
JACC Heart Fail; 2019 Jan; 7(1):25-32. PubMed ID: 30606484
[TBL] [Abstract][Full Text] [Related]
38. Spironolactone in Patients With an Echocardiographic HFpEF Phenotype Suggestive of Cardiac Amyloidosis: Results From TOPCAT.
Sperry BW; Hanna M; Shah SJ; Jaber WA; Spertus JA
JACC Heart Fail; 2021 Nov; 9(11):795-802. PubMed ID: 34509404
[TBL] [Abstract][Full Text] [Related]
39. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry.
Senni M; Gavazzi A; Oliva F; Mortara A; Urso R; Pozzoli M; Metra M; Lucci D; Gonzini L; Cirrincione V; Montagna L; Di Lenarda A; Maggioni AP; Tavazzi L;
Int J Cardiol; 2014 May; 173(2):163-9. PubMed ID: 24630337
[TBL] [Abstract][Full Text] [Related]
40. The frailty syndrome and outcomes in the TOPCAT trial.
Sanders NA; Supiano MA; Lewis EF; Liu J; Claggett B; Pfeffer MA; Desai AS; Sweitzer NK; Solomon SD; Fang JC
Eur J Heart Fail; 2018 Nov; 20(11):1570-1577. PubMed ID: 30225878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
